Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients

被引：6
|
作者：
Magen, I. [1 ]
Aharoni, S. [2 ]
Yacovzada, N. [1 ]
Latzer, I. Tokatly [3 ]
Alves, C. [4 ]
Sagi, L. [3 ]
Fattal-Valevski, A. [3 ]
Swoboda, K. [4 ]
Katz, J. [2 ]
Bruckheimer, E. [2 ]
Nevo, Y. [2 ]
Hornstein, E. [1 ]
机构：
[1] Weizmann Inst Sci, Rehovot, Israel
[2] Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel
[3] Dana Dwek Childrens Hosp, Tel Aviv, Israel
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
NEUROMUSCULAR DISORDERS | 2022年 / 32卷
关键词：
D O I：
10.1016/j.nmd.2022.07.089
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.53
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 50 条
  • [41] Respiratory outcomes post nusinersen in spinal muscular atrophy type 1
    Gonski, Kate
    Fitzgerald, Dominic A.
    PEDIATRIC PULMONOLOGY, 2021, 56 (05) : 807 - 808
  • [42] Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
    Mirea, Andrada
    Shelby, Elena-Silvia
    Axente, Mihaela
    Badina, Mihaela
    Padure, Liliana
    Leanca, Madalina
    Dima, Vlad
    Sporea, Corina
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [43] Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec
    Matesanz, Susan E.
    Curry, Candace
    Gross, Brianna
    Rubin, Adam I.
    Linn, Rebecca
    Yum, Sabrina W.
    Kichula, Elizabeth A.
    JOURNAL OF CHILD NEUROLOGY, 2020, 35 (11) : 717 - 723
  • [44] The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy
    Uzan, Gamze Sarikaya
    Paketci, Cem
    Gunay, Cagatay
    Edem, Pinar
    Ozsoy, Ozlem
    Kurul, Semra Hiz
    Yis, Uluc
    NEUROPEDIATRICS, 2022, 53 (05) : 321 - 329
  • [45] Immunization status of patients with spinal muscular atrophy receiving nusinersen therapy
    Yesilmen, Mehmet Can
    Gunay, Cagatay
    Uzan, Gamze Sarikaya
    Ozsoy, Ozlem
    Kurul, Semra Hiz
    Yis, Uluc
    ARCHIVES DE PEDIATRIE, 2023, 30 (05): : 291 - 296
  • [46] Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study
    Shimizu-Motohashi, Yuko
    Chiba, Emiko
    Mizuno, Katsuhiro
    Yajima, Hiroyuki
    Ishiyama, Akihiko
    Takeshita, Eri
    Sato, Noriko
    Oba, Mari
    Sasaki, Masayuki
    Ito, Shuichi
    Komaki, Hirofumi
    BRAIN & DEVELOPMENT, 2023, 45 (03): : 161 - 170
  • [47] The light at the end of the tunnel gets vivid for spinal muscular atrophy An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on
    Dutta, Debashis
    Chandra, Goutam
    Mohanakumar, Kochupurackal P.
    JOURNAL OF NEUROCHEMISTRY, 2020, 153 (05) : 545 - 548
  • [48] Type III Spinal Muscular Atrophy Mimicking Muscular Dystrophies
    Alsaman, Abdulaziz S.
    AlShaikh, Nahla M.
    PEDIATRIC NEUROLOGY, 2013, 48 (05) : 363 - 366
  • [49] First experience of Nusinersen early access program in patients with spinal muscular atrophy type 1
    Gargaun, E.
    Aragon-Gawinska, K.
    Seferian, A.
    Gidaro, T.
    Gilabert, S.
    Lilien, C.
    Colcer, A.
    Boukouti, K.
    Vuillerot, C.
    Cances, C.
    Daron, A.
    Annousamy, M.
    De, A.
    Berliac, L. Flet
    Armier, H.
    Fiedler, L.
    Servais, L.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S211 - S212
  • [50] Characterization of patients with Type 1 Spinal Muscular Atrophy in advanced disease state treated with Nusinersen
    Balkenhol, J.
    Beytia, M.
    Jofre, J.
    Suarez, B.
    Hervias, C.
    Calcagno, G.
    Castiglioni, C.
    NEUROMUSCULAR DISORDERS, 2024, 43
12345